Does the Time of Onset of Urinary Symptoms Affect Microablative Fractional CO
fractional CO2 laser
lower urinary tract symptoms
menopause
overactive bladder
urinary symptoms
vulvovaginal atrophy
Journal
Lasers in surgery and medicine
ISSN: 1096-9101
Titre abrégé: Lasers Surg Med
Pays: United States
ID NLM: 8007168
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
28
12
2020
received:
08
07
2020
accepted:
31
12
2020
pubmed:
22
1
2021
medline:
29
10
2021
entrez:
21
1
2021
Statut:
ppublish
Résumé
To evaluate the safety and efficacy of transvaginal fractional microablative CO This is a retrospective analysis of prospectively collected data. Postmenopausal women affected by at least one urinary symptom (urinary frequency, urgency incontinence, stress urinary incontinence) and VVA symptom each (dryness, dyspareunia, itching, burning) were enrolled. Our population was divided into two groups in relation to the onset of urinary symptoms, prior to or after menopause. Women were treated with three CO Sixty-one women were enrolled in this study. Overall, at T1 MLT brought to a significant improvement in urinary symptoms (P < 0.05) in women with urinary symptoms started after the menopause (Group B), contrary to the ones with urinary symptoms started before the menopause (Group A). Specifically, urinary frequency significantly improved only in Group B (P < 0.05), while urgency incontinence, significantly reduced in both groups (P < 0.05). Stress urinary incontinence did not significantly improve in both groups (P > 0.05). Secondary, all VVA symptoms showed a statistically significant improvement (P < 0.05) at 16 weeks from baseline; no differences were registered between groups. No adverse events were recorded. This study confirms the safety and efficacy of CO
Sections du résumé
BACKGROUND AND OBJECTIVE
To evaluate the safety and efficacy of transvaginal fractional microablative CO
STUDY DESIGN/MATERIALS AND METHODS
This is a retrospective analysis of prospectively collected data. Postmenopausal women affected by at least one urinary symptom (urinary frequency, urgency incontinence, stress urinary incontinence) and VVA symptom each (dryness, dyspareunia, itching, burning) were enrolled. Our population was divided into two groups in relation to the onset of urinary symptoms, prior to or after menopause. Women were treated with three CO
RESULTS
Sixty-one women were enrolled in this study. Overall, at T1 MLT brought to a significant improvement in urinary symptoms (P < 0.05) in women with urinary symptoms started after the menopause (Group B), contrary to the ones with urinary symptoms started before the menopause (Group A). Specifically, urinary frequency significantly improved only in Group B (P < 0.05), while urgency incontinence, significantly reduced in both groups (P < 0.05). Stress urinary incontinence did not significantly improve in both groups (P > 0.05). Secondary, all VVA symptoms showed a statistically significant improvement (P < 0.05) at 16 weeks from baseline; no differences were registered between groups. No adverse events were recorded.
CONCLUSION
This study confirms the safety and efficacy of CO
Substances chimiques
Carbon Dioxide
142M471B3J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
953-959Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Portman DJ , Gass ML , Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: New terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society. Climacteric 2014;17:557-563.
Hutchinson-Colas J , Segal S . Genitourinary syndrome of menopause and the use of laser therapy. Maturitas 2015;82:342-345.
Zerbinati N , Serati M , Origoni M , Candiani M , Iannitti T , Salvatore S , et al. Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional carbon dioxide laser treatment. Lasers Med Sci 2014;30(1):429-436.
Gandhi J , Chen A , Dagur G , Suh Y , Smith N , Cali B , et al. Genitourinary syndrome of menopause: An overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol 2016. 704-711.
Wysocki S , Kingsberg S , Krychman M . Management of vaginal atrophy: Implications from the REVIVE survey. Clin Med Insights Reprod Health 2014;8:23-30.
Nappi RE , Particco M , Biglia N , et al. Attitudes and perceptions towards vulvar and vaginal atrophy in Italian post-menopausal women: Evidence from the European REVIVE survey. Maturitas 2016;91:74-80.
Nappi RE , Palacios S , Panay N , et al. Vulvar and vaginal atrophy in four European countries: Evidence from the European REVIVE survey. Climacteric 2016;19:188-197.
Juliato CR , Baccaro LF , Pedro AO , et al. Factors associated with urinary incontinence in middle-aged women: A population-based household survey. Int Urogynecol J 2017;28:423-429.
Bortolotti A , Bernardini B , Colli E , et al. Prevalence and risk factors for urinary incontinence in Italy. Eur Urol 2000;37:30-35.
Quinn SD , Domoney C . The effects of hormones on urinary incontinence in postmenopausal women. Climacteric 2009;12:106-113.
Legendre G , Ringa V , Fauconnier A , Fritel X . Menopause, hormone treatment and urinary incontinence at midlife. Maturitas 2013;74:26-30.
Ewies AA , Alfhaily F . Topical vaginal estrogen therapy in managing postmenopausal urinary symptoms: A reality or a gimmick? Climacteric 2010;13:405-418.
Kobata SA , Girao MJ , Baracat EC , et al. Estrogen therapy influence on periurethral vessels in postmenopausal incontinent women using Doppler velocimetry analysis. Maturitas 2008;61:243-247.
Jarmy-DiBella ZI , Girao MJ , DiBella V , et al. Hormonal influence on periurethral vessels in postmenopausal incontinent women using Doppler velocimetry analysis. Maturitas 2007;56:297-302.
Archer DF , Goldstein SR , Simon JA , et al. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: A phase 3, randomized, double-blind, placebo-controlled, multicenter trial. Menopause 26(6):611-621.
Sturdee DW , Panay N . Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010;13:509-522.
Management of symptomatic vulvovaginal atrophy: 2013 position statement of the North American Menopause Society. Menopause 2013;20:888-902.
Ettinger B , Hait H , Reape KZ , et al. Measuring symptom relief in studies of vaginal and vulvar atrophy: the most bothersome symptom approach. Menopause 2008;15:885-889.
Parish SJ , Nappi RE , Rychman ML , et al. Impact of vulvovaginal health on postmenopausal women: A review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health 2013;5:437-447.
Oge T , Hassa H , Aydin Y , et al. The relationship between urogenital symptoms and climacteric complaints. Climacteric 2013;16:646-652.
Lester J , Pahouja G , Andersen B , et al. Atrophic vaginitis in breast cancer survivors: A difficult survivorship issue. J Pers Med 2015;5:50-66.
Crandall C , Petersen L , Ganz PA , et al. Association of breast cancer and its therapy with menopause-related symptoms. Menopause 2004;11:519-530.
Castelo-Branco C , Cancelo MJ , Villero J , Nohales F , Julia MD . Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas 2005;52(SUPPL. 1):46-52.
Portman DJ , Bachmann GA , Simon JA . Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause 2013;20(6):623-630.
Rahn DD , Carberry C , Sanses TV , et al. Vaginal estrogen for genitourinary syndrome of menopause: A systematic review. Obstet Gynecol 2014;124(6):1147-1156.
Kingsberg S , Krychman M , Graham S , et al. The Women's EMPOWER survey: Identifying women's perceptions on vulvar and vaginal atrophy (VVA) and treatment. Presented at the 27th Annual Meeting of The North American Menopause Society October 5e8, 2016, Orlando, FL (S-10). Menopause 2016;23:1363-1407.
Su C-F , Chen G-D , Tsai H-J Preliminary outcome of non-ablative vaginal Erbium laser treatment for female stress and mixed urinary incontinence. Taiwan J Obstet Gynecol 2019;58(5):610-613.
Salvatore S , Leone Roberti Maggiore U , Athanasiou S , et al. Histological study on the effects of microablative fractional CO2 laser on atrophic vaginal tissue: An ex vivo study. Menopause 2015;22:845-849.
Salvatore S , Leone Roberti Maggiore U , Origoni M , et al. Microablative fractional CO2 laser improves dyspareunia related to vulvovaginal atrophy: A pilot study. J Endom Pelvic Pain Disord 2014;6:150-156.
Salvatore S , Nappi RE , Zerbinati N , et al. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: A pilot study. Climacteric 2014;17:363-369.
Salvatore S , Nappi RE , Parma M , et al. Sexual function after fractional microablative CO2 laser in women with vulvovaginal atrophy. Climacteric 2015;18:219-225.
Perino A , Calligaro A , Forlani F , et al. Vulvo-vaginal atrophy: A new treatment modality using thermo-ablative fractional CO2 laser. Maturitas 2015;80:296-301.
Pieralli A , Fallani MG , Becorpi A , et al. Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors. Arch Gynecol Obstet 2016;294:841-846.
Perino A , Cucinella G , Gugliotta G , et al. Is vaginal fractional CO2 laser treatment effective in improving overactive bladder symptoms in post-menopausal patients? Preliminary results. Eur Rev Med Pharmacol Sci 2016;20:841-846.
Sokol ER , Karram MM . An assessment of the safety and efficacy of fractional CO2 laser system for the treatment of vulvovaginal atrophy. Menopause 2016;23:1102-1107.29.
Athanasiou S , Pitsouni E , Antonopoulou S , et al. The effect of microablative fractional CO2 laser on vaginal flora of postmenopausal women. Climacteric 2016;19:512-518.
Murina F , Karram M , Salvatore S , Felice R . Fractional CO2 laser treatment of the vestibule for patients with vestibulodynia and genitourinary syndrome of menopause: A pilot study. J Sex Med 2016;13:1915-1917.
Pitsouni E , Grigoriadis T , Tsiveleka A , Zacharakis D , Salvatore S , Athanasiou S . Microablative fractional CO2 laser therapy and the genitourinary syndrome of menopause: An observational study. Maturitas 2016;94:131-136.
Tovar-Humani J , Mercado-Olivares F , Grandez-Urbina JA , Pichardo-Rodriguez R , Tovar-Huamani M , Garcia-Perdomo H . Efficacy of fractional CO2 laser in the treatment of genitourinary syndrome of menopause in Latin-American population: First Peruvian experience. Laser Surg Med. 2019;51(6):509-515.
Perino A , Cucinella G , Gugliotta G , et al. Is vaginal fractional CO2 laser treatment effective in improving overactive bladder symptoms in post-menopausal patients? Preliminary results. Eur Rev Pharmacol Sci 2016 Jun;20(12):2491.
Sipos AG , Kozma B , Poka R , Larson K , Takacs P . The effect of fractional CO2 laser treatment on the symptoms of pelvic floor dysfunctions: Pelvic Floor Distress Inventory-20 Questionnaire. Lasers Surg Med 2019;51(10):882-886.
Bump RC , Mattiasson A , Bø K , et al. The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. Am J Obstet Gynecol 1996;175:10-17.
Bradley CS , Rovner ES , Morgan MA , et al. A new questionnaire for urinary incontinence diagnosis in women: development and testing. Am J Obstet Gynecol 2005;192(1):66-73.
Abrams P , Avery K , Gardener N , Donovan J , ICIQ Advisory Board. The International Consultation on Incontinence Modular Questionnaire. J Urol 2006;175(3 Pt 1):1063-1066.
Haylen BT , De Ridder D , Freeman RM , et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol. Urodyn. 2010. 4-20.
Marjoribanks J , Farquhar C , Roberts H , Lethaby A , Lee J . Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2017;1(1):CD004143. https://doi.org/10.1002/14651858.CD004143.pub5
Salvatore S , Delancey J , Igawa Y , et al. Pathophysiology of urinary incontinence, faecal incontinence and pelvic organ prolapse. Incontinence 2017. 364-385.
Versi E , Cardozo LD . Oestrogens and lower urinary tract symptoms. In: Studd JWW , Whitehead MI , editors. The Menopause. Oxford: Blackwell Scientific Publications; 1988; 32:pp 273-280.
Yamada T , Ugawa S , Ueda T , Ishida Y , Kajita K , Shimada S . Differential localizations of the transient receptor potential channels TRPV4 and TRPV1 in the mouse urinary bladder. J Histochem Cytochem 2009;57(3):277-287.
Charrua A , Reguenga C , Cordeiro JM , et al. Functional transient receptor potential vanilloid 1 is expressed in human urothelial cells. J Urol 2009;182(6):2944-2950.
Ulmesten U . Some reflections and hypotheses on the pathophysiology of female urinary incontinence. Acta Obstet Gynecol Scand Suppl 1997;166:3-8.